Temanogrel (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name APD791) is a serotonin 5-HT2A receptor antagonist and inverse agonist which is under development for the treatment of myocardial ischemia and Raynaud's disease. It was also being developed for arterial thrombosis and acute coronary syndromes, but development for the former use was suspended and development for the latter indication was discontinued. The drug is taken orally. Temanogrel is highly selective for the serotonin 5-HT2A receptor, with more than 2,000-fold selectivity for this receptor over the serotonin 5-HT2B and 5-HT2C receptors and lack of activity at a variety of other G protein-coupled receptors (GPCRs). As of September 2022, it is in phase 2 clinical trials for myocardial ischemia and Raynaud's disease.
See also Serotonin 5-HT2A receptor antagonist
References